253 related articles for article (PubMed ID: 7536607)
1. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
2. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
3. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
4. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
5. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
8. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
9. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
[TBL] [Abstract][Full Text] [Related]
10. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
11. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
13. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
15. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
[TBL] [Abstract][Full Text] [Related]
16. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?
Yap BK; Choo R; Deboer G; Klotz L; Danjoux C; Morton G
BJU Int; 2003 May; 91(7):613-7. PubMed ID: 12699470
[TBL] [Abstract][Full Text] [Related]
17. How significant are serial bone scans in monitoring advanced prostatic cancer?
Tekgül S; Ozen H; Ozyavuz R; Bakkaloğlu M; Remzi D
Int Urol Nephrol; 1995; 27(1):87-91. PubMed ID: 7615375
[TBL] [Abstract][Full Text] [Related]
18. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
19. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Oommen R; Geethanjali FS; Gopalakrishnan G; Chacko N; John S; Kanagasabapathy AS; Roul RK
Br J Radiol; 1994 May; 67(797):469-71. PubMed ID: 7514940
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
